PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
26.95%
R&D change of 26.95% versus flat Healthcare spending. Walter Schloss would verify adequacy.
24.63%
G&A change of 24.63% versus flat Healthcare overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
3.65%
Other expenses change of 3.65% versus flat Healthcare costs. Walter Schloss would verify efficiency.
26.14%
Operating expenses growth exceeding 1.5x Healthcare median of 0.54%. Jim Chanos would check for waste.
26.14%
Total costs growth exceeding 1.5x Healthcare median of 0.78%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
3.65%
D&A growth exceeding 1.5x Healthcare median of 1.05%. Jim Chanos would check for overinvestment.
-26.20%
EBITDA decline while Healthcare median is 0.37%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-26.14%
Operating income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-1.70%
Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
-26.43%
Pre-tax income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.43%
Net income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-26.52%
EPS decline while Healthcare median is 3.19%. Seth Klarman would investigate causes.
-26.52%
Diluted EPS decline while Healthcare median is 3.13%. Seth Klarman would investigate causes.
0.09%
Share count reduction below 50% of Healthcare median of 0.15%. Jim Chanos would check for issues.
0.09%
Diluted share reduction exceeding 1.5x Healthcare median of 0.20%. Joel Greenblatt would investigate strategy.